The effect of curcumin and placebo on human gall‐bladder function: an ultrasound study

Rasyid, Abdul; Lelo, Aznan

doi:10.1046/j.1365-2036.1999.00464.x

Cited by 84 publications

(46 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Agents that can induce the gall bladder to contract and empty itself (e.g., erythromycin, fatty meals, and amino acids) have been shown to reduce gallstone formation. In a randomized, double-blind, crossover study involving 12 healthy volunteers [178], 20 mg curcumin produced a positive cholekinetic effect that led to 29% contraction of the gall bladder. A subsequent study indicated that doses of 40 and 80 mg curcumin produced 50% and 72% contraction of the gall bladder volume, respectively.…”

Section: Curcumin May Prevent Gallstone Formationmentioning

confidence: 99%

Curcumin as “Curecumin”: From kitchen to clinic

Goel

Kunnumakkara

Aggarwal

2008

Biochemical Pharmacology

1,906

1,290

View full text Add to dashboard Cite

Section: Curcumin May Prevent Gallstone Formationmentioning

confidence: 99%

Curcumin as “Curecumin”: From kitchen to clinic

Goel

Kunnumakkara

Aggarwal

2008

Biochemical Pharmacology

1,906

1,290

View full text Add to dashboard Cite

“…Previous studies showed that high concentration of curcumin causes chromosome aberrations, astrocyte cell death, teratogenic effect, embryo-, and reproductive toxicities (Ganiger and others 2007;Wu and others 2007; BurgosMorón and others 2010; Romero-Hernández and others 2013). Rasyid and Lelo (1999) found that curcumin should not recommend for gallstones patients inasmuch as it induces contraction of human gallbladder.…”

Section: Safetymentioning

confidence: 99%

Curcumin and Liver Disease: from Chemistry to Medicine

Nabavi

Daglia

Moghaddam

et al. 2013

Comp Rev Food Sci Food Safe

172

View full text Add to dashboard Cite

Curcumin, the natural yellow-colored active principle, also called turmeric yellow, extracted from the perennial herb Curcuma longa L., has potent biological and pharmacological properties such as antioxidant, anti-inflammatory, antifungal, antibacterial, anti-ischemic, antitumor, and anticancer actions. The molecular mechanism of the hepatoprotective action of curcumin is due to its antioxidant properties and inhibitory activity against nuclear factor (NF)-κB that regulates different proinflammatory and profibrotic cytokines. Overall, scientific reports demonstrate that curcumin has high therapeutic ability for treating hepatic disorders. Here is a systematic discussion of the hepatoprotective activity of curcumin and its possible mechanisms of actions.

show abstract

“…A single oral dose of 20 mg of curcumin appeared to induce contraction of the gallbladder as adjudged by ultrasound scanning in human volunteers, compared to an amylum placebo. 55 Two potential surrogate biomarkers of the efficacy of curcumin were evaluated in the blood of patients with advanced colorectal cancer who received up to 180 mg of curcumin per day for up to 4 months. 56 In three patients on 36 mg of curcumin daily, lymphocytic activity of GST was decreased with time to reach 41% of control (untreated) on day 29 of treatment.…”

Section: Dose-effect Relationshipsmentioning

confidence: 99%

Pharmacokinetics and Pharmacodynamics of Curcumin

Sharma¹,

Steward²,

Gescher³

2007

Advances in Experimental Medicine and Biology

385

251

View full text Add to dashboard Cite

Curcuma spp. contain turmerin, essential oils, and curcuminoids, including curcumin. Curcumin [1,7-bis-(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione] is regarded as the most biologically active constituent of the spice turmeric and it comprises 2-8% of most turmeric preparations. Preclinical data from animal models and phase I clinical studies performed with human volunteers and patients with cancer have demonstrated low systemic bioavailability following oral dosing. Efficient first-pass metabolism and some degree of intestinal metabolism, particularly glucuronidation and sulfation of curcumin, might explain its poor systemic availability when administered via the oral route. A daily oral dose of 3.6 g of curcumin is compatible with detectable levels of the parent compound in colorectal tissue from patients with cancer. The levels demonstrated might be sufficient to exert pharmacological activity. There appears to be negligible distribution of the parent drug to hepatic tissue or other tissues beyond the gastrointestinal tract. Curcumin possesses wide-ranging anti-inflammatory and anticancer properties. Many of these biological activities can be attributed to its potent antioxidant capacity at neutral and acidic pH, its inhibition of cell signaling pathways at multiple levels, its diverse effects on cellular enzymes, and its effects on cell adhesion and angiogenesis. In particular, curcumin's ability to alter gene transcription and induce apoptosis in preclinical models advocates its potential utility in cancer chemoprevention and chemotherapy. With regard to considerable public and scientific interest in the use of phytochemicals derived from dietary components to combat or prevent human diseases, curcumin is currently a leading agent.

show abstract

The effect of curcumin and placebo on human gall‐bladder function: an ultrasound study

Abstract: On the basis of the present findings, it appears that curcumin induces contraction of the human gall-bladder.

Cited by 84 publications

References 7 publications

Curcumin as “Curecumin”: From kitchen to clinic

Curcumin as “Curecumin”: From kitchen to clinic

Curcumin and Liver Disease: from Chemistry to Medicine

Pharmacokinetics and Pharmacodynamics of Curcumin

Contact Info

Product

Resources

About